The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials is a paper indexed in ScholarIQ from OpenAlex.
How many citations does The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials have?
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials has 5 citations in the OpenAlex counts ScholarIQ stores.
When was The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials published?
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials has 2023 year in the ScholarIQ index.
What is the open-access status of The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials?
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials has bronze oa status in the ScholarIQ index.
What is the DOI of The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials?
The DOI for The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials is on the source record.
What is the PMID of The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials?
The PMID for The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials is on the source record.
What is the OpenAlex record for The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials?
The OpenAlex for The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the <scp>STEP</scp> 1‐4 obesity trials is on the source record.